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Editorial on the Research Topic
Non-invasive Brain Stimulation in Neurology and Psychiatry
In recent years, greater attention has been paid to alternative treatments in neurology and
psychiatry, with the main aim of restoring or “normalizing” function in aberrant brain circuits,
in order to have a positive impact on the patient’s quality of life. Non-invasive brain stimulation
(NIBS) methods such as transcranial magnetic stimulation (TMS) or transcranial direct current
stimulation (tDCS) have been increasingly used not only in research but also in clinical settings.
To date, depression is the only psychiatric disorder for which TMS has been approved and used
extensively as a therapeutic approach (Padberg and George, 2009; George et al., 2013). Meanwhile,
application of NIBS for other brain disorders such as tinnitus, chronic pain, migraine, dementia,
Parkinson’s disease (PD), and dystonia are currently in development by optimizing key parameters
such as the most appropriate brain target, stimulation protocols and candidate symptoms to
treat. Thus, while there has been relatively wide interest in clinical applications of NIBS, yet
with refinement of techniques, future improvement of protocols and the possibility of achieving
more prolonged and longer-lasting beneficial effects, we believe NIBS will potentially become an
approved therapeutic approach for some disorders. The current Special Issue is a compilation of
literature reviews or experimental studies using TMS or tDCS as a therapeutic tool in different
neurological and psychiatric disorders.
NON-INVASIVE BRAIN STIMULATION METHODS AS
THERAPEUTIC TOOLS
The 16 papers in the current Research Topic demonstrate the value of NIBS in the psychiatry and
neurology domains and also in cognitive training.
Evidence reveals TMS (Dunlop et al.) and tDCS (Sauvaget et al.) as effective methods for
reducing craving in people suffering from eating disorders. A comprehensive review of eating
disorders (anorexia, bulimia, and binge eating) confirms the positive use of repetitive TMS (rTMS)
to reduce relapse rates. The suggested brain target area is the dorsolateral prefrontal cortex
(DLPFC), with incremental clinical success with 10 repeated stimulation sessions. The clinical
changes are considered to be potentially associated with improved cognitive control or conflict
processing (Dunlop et al.), both prefrontal cortex functions. Similar results have been shown with
tDCS, although in fewer studies (Sauvaget et al.). These studies used clinical ratings by patients
as measures of stimulation induced change, as they are considered to more accurately reflect
the patient’s experience and expectations, albeit that they are subject to the common biases of
self-report measures, highlighting the need for inclusion of sham-controlled conditions to control
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for potential placebo effects. A validated method is to combine
brain stimulation with imaging (Bestmann et al., 2004). In
fact, imaging has proved essential in understanding the positive
response to TMS in depression, as shown by a link between
clinical improvement and changes in cingulate activity (Fox et al.,
2012).
A succinct overview on use of NIBS for auditory
hallucinations highlights the efficacy of rTMS and TDCS in
reducing the frequency of hallucinations (Moseley et al.).
Higher temporo-parietal junction activity (mainly left-sided)
is a potential source of hallucinations (Homan et al., 2012),
which identifies this as the target location for NIBS. Repeated
sessions during 5 consecutive days of cathodal tDCS reduced the
hallucinations and this improvement persisted for a 3-month
period. In their review, the authors considered the value and
efficacy of transcranial random noise stimulation (tRNS) or
transcranial alternating current stimulation (tACS) as potential
future treatments for hallucination. An additional meta-analysis
on conversion disorder shows in 75/86 patients under rTMS
treatment a marked improvement as measured by clinical scales
(Schönfeldt-Lecuona et al.), which gives further support for
NIBS tools in complex neuropsychiatric conditions.
In recent years, application of NIBS in the treatment of
neurological patients has been gaining pace and the use of
both TMS and tDCS in neurological conditions such as stroke
(Corti et al., 2012), tinnitus (Fregni et al., 2006), and PD (Koch
et al., 2009) has been evaluated (for review see Obeso et al.).
Yet, proof-of-principle studies are needed in treating specific
neurological symptoms and to date beneficial changes are limited
to acute effects, with limited long-lasting effects. Following the
NIBS research approach in depression, larger and well-controlled
clinical trials (i.e., use of placebo condition and coils), with
longer follow-up periods are urgently needed to confirm the value
of stimulation protocols with enhanced durability of clinical
benefits.
TMS is useful for differential diagnosis in tremor or stroke
by using motor evoked potentials (Brum et al.). Moreover, a
classical clinical use of TMS has been to measure cortico-spinal
integrity through examining the functioning of the cortico-
spinal tracts after stimulation of motor regions. This method
is adequate for differential diagnosis based on central motor
conduction time (the time taken from TMS pulse activation of
the motor cortex and firing of spinal motor neurons). The use
of TMS and diffusion tensor imaging showed in stroke patients
a correlation between the speed of conduction in the cortico-
spinal tract and the integrity of premotor and supplementary
tracts (but not the motor area) (Potter-Baker et al.). Their results
are of interest for understanding how stroke patients compensate
by using higher-order motor control regions upon fatal loss of
the principal motor cortical area. For long-term effects, rTMS
for stroke treatment is becoming more and more promising
as positive findings are being replicated. In the current special
topic, authors report in stroke patients how consecutive rTMS
session resulted in movement improvement (Di Lazzaro et al.)
but also increased tactile detection (Fujimoto et al.). Sample size
and gender effects need attention in stroke research as they seem
to interact when using rTMS as a treatment tool (Chalah et al.;
Di Lazzaro et al.). Last, patients with chronic pain not responsive
to pharmacological treatment may benefit from NIBS tools over
the primary motor region (DosSantos et al.), whereby distant
changes in cortico-subcortical structures and neurotransmitter
modulation (serotonin, GABA, glutamate) were associated to
clinical improvement.
There is also a novel contribution from light therapy used as a
NIBS protocol (see Johnstone et al.). The use of light stimulation
has been tested on animal models of PD and AD using low-
level near infrared light (NIr) therapy (Shaw et al., 2010; De
Taboada et al., 2011), reported to lessen behavioral deficits in both
animal models. It is noted that this procedure did not produce
any beneficial effects in AD or PD (Johnstone et al.). Only a non-
controlled and non-randomized clinical report showed some
improvement in speech, some aspects of cognition and gait after
NIr therapy in PD patients (Maloney et al., 2010), which needs to
be replicated in a larger sample in a better controlled study. Thus,
based on valid animal models, Nlr therapy warrants evaluation in
larger samples in well-controlled studies, with other targets, and
selection of intracranial or extracranial approaches based on the
disease, to allow future clinical application.
New avenues of positive results are also obtained in attempts
to improve cognitive functioning. AD patients showed improved
working memory after tDCS and this was associated to changes
in high-frequency bands (Marceglia et al.). However, the use of
associated paradigms such as exercise (Morris et al., 2016) or
cognitive rehabilitation (Cappon et al.) will boost the cognitive
remediation and positive effects.
FUTURE WORK
There are a number of parallel issues across the therapeutic
applications of NIBS that need to be addressed. The ultimate
value of NIBS rests on proving it to be an efficient and long-
lasting therapy that alleviates patient’s specific psychiatric,
neurological or cognitive symptomatology. However, the
questions of where, how and when to stimulate are essential to be
addressed in order to follow the logical steps to reach maximal
NIBS efficacy for different symptoms and disorders. Although
candidate cortical regions to act as targets for receiving NIBS are
somewhat more clear for some neurological conditions, other
neurological and psychiatric disorders still require evidence
from imaging and physiological studies to identify the region or
network to be targeted with NIBS. A critical factor is the inclusion
of repeated stimulation sessions to achieve potentiation effects.
This may be done with an initial period of daily stimulation
for example 5 days of consecutive stimulation, followed by
once a week booster sessions. Other procedural issues may also
influence the quality and efficacy of the NIBS such as the state
or subject dependency of the effects, use of neuronavigation vs.
EEG localization of the target and these require due attention in
future investigations. New methods to better quantify potential
beneficial effects of NIBS are the use of models that account for
long-term effects (Mahmud and Vassanelli). In future trials, to
ensure that NIBS is cost-effective compared to standard medical
therapy, there is a need to maximize the efficacy and positive
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outcomes of NIBS protocols. Sham-controlled randomized
trials of NIBS are essential. Moreover, if the symptoms to be
treated have a high within subject variability (e.g., pain, tinnitus
and psychiatric symptoms) the clinical trials required could
be even more complex and expensive. Using a telemedicine
approach and/or using smartphone and wearable technology,
continuous patient evaluation can be easier. This will allow NIBS
technologies to be tested in a more efficient way.
It is also extremely important to reconsider NIBS variability
at individual level. The same target with the same NIBS
protocol may produce different effects in different individuals.
A personalized approach is needed to reduce this source of
variability. Nowadays, many technological tools are available
for evaluating central nervous system disorders. However, the
general approach is to apply a single therapy or an isolated
technology to find the way to help a group of patients that
have a common etiology but sometimes very different nervous
system pathology and clinical presentations. It is necessary to
find the perfect combination of assessment methods to evaluate
symptoms and their change after application of a smart mix
of therapeutic options, applied at a given time and at the
appropriate “doses” to face the great complexity of neurological
and psychiatric problems. This may be one of the future strategies
for NIBS therapies to find a place in psychiatric and neurological
clinics.
Finally, there is a need for safe, efficient and cost-
effective NIBS methods such as transcranial static magnetic
field stimulation (tSMS) or tDCS that can be portable
and usable in patients’ homes, which would facilitate
generalization of the treatment to the patients’ daily life
environment.
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